This study evaluates the analytical reliability of direct-to-consumer (DTC) gut microbiome testing services. As consumer interest in gut health rises, many companies now offer home stool tests that claim to analyze microbiome composition and provide health or dietary recommendations. However, the scientific validity of these tests remains uncertain.
Researchers tested seven commercial microbiome testing companies using a standardized stool reference sample developed by the National Institute of Standards and Technology (NIST). Each company received identical samples to analyze using their own sequencing and analytical pipelines.
Key Findings
- Large inconsistencies between companies: The same stool sample produced very different microbiome profiles depending on the company analyzing it.
- Methodological variability was high: Differences in sampling, DNA extraction, sequencing methods (16S vs. whole-genome sequencing), and bioinformatics pipelines created major discrepancies.
- Variability rivaled biological differences: The variation between companies analyzing the same sample was as large as or larger than differences between different human donors.
- Low agreement on microbial taxa: Out of more than 1,200 detected genera, only a small fraction appeared consistently across all tests.
- Conflicting health interpretations: Some companies classified the same microbiome sample as healthy, while others labeled it unhealthy, leading to contradictory recommendations.
Why This Matters
The findings suggest that many consumer microbiome tests lack standardization and analytical reliability, meaning results from different companies may not be comparable or clinically meaningful. This raises concerns about consumers making dietary changes, supplement purchases, or health decisions based on inconsistent data.